Cannabinoid Poisoning Follow-up
- Author: Ani Aydin, MD; Chief Editor: Robert G Darling, MD, FACEP more...
Patient Education
- Educate all patients with cannabis use or abuse about the adverse effects of this drug. Encouraging cessation is equally important.
- An effort should be made to educate patients on the adverse effects of cannabis use which include the following:
- Impaired attention, memory, and psychomotor performance that occur while intoxicated
- Subtle changes in attention and memory that occur with chronic use
- Increased risk of motor vehicle collisions if driving while intoxicated.
- Chronic bronchitis and histopathological changes of the cavity or respiratory tract that may be cancerous precursors
- For excellent patient education resources, visit eMedicine's Bioterrorism and Warfare Center. Also, see eMedicine's patient education articles Biological Warfare and Personal Protective Equipment.
Wells DL, Ott CA. The "new" marijuana. Ann Pharmacother. Mar 2011;45(3):414-7. [Medline].
Kuepper R, van Os J, Lieb R, Wittchen HU, Höfler M, Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ. Mar 1 2011;342:d738. [Medline]. [Full Text].
National Institute on Drug Abuse, National Institutes of Health, Centers for Substance Abuse Prevention and Treatment. National Conference on Marijuana Use: Prevention, VA. Treatment and Research. NIH publication. 1995: Arlington;38-49:no 96-4106. [Full Text].
National Institute on Drug Abuse. InfoFacts: Marijuana. Updated April 2006. [Full Text].
Pavarin RM, Berardi D. Mortality risk in a cohort of subjects reported by authorities for cannabis possession for personal use. Results of a longitudinal study. Epidemiol Prev. Mar-Apr 2011;35(2):89-93. [Medline].
Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction. Nov 1996;91(11):1585-614. [Medline].
Ashton CH. Adverse effects of cannabis and cannabinoids. Br J Anaesth. Oct 1999;83(4):637-49. [Medline].
Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry. Feb 2001;178:101-6. [Medline].
Compton WM, Grant BF, Colliver JD, Glantz MD, Stinson FS. Prevalence of marijuana use disorders in the United States: 1991-1992 and 2001-2002. JAMA. May 5 2004;291(17):2114-21. [Medline].
Degenhardt L, Hall W, Lynskey M. Exploring the association between cannabis use and depression. Addiction. Nov 2003;98(11):1493-504. [Medline].
Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-60. [Medline].
Hall W, Solowij N. Adverse effects of cannabis. Lancet. Nov 14 1998;352(9140):1611-6. [Medline].
Hall W, Solowij N, Lemon J:. The Health and Psychological Consequences of Cannabis Use. Monograph No 25. National Drug Strategy. Australian Government Publication Serv. 1994;15-20.
Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A. Mar 1990;87(5):1932-6. [Medline].
Huestis MA, Mitchell JM, Cone EJ. Detection times of marijuana metabolites in urine by immunoassay and GC-MS. J Anal Toxicol. Oct 1995;19(6):443-9. [Medline].
Kalant H. Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry. Aug 2004;28(5):849-63. [Medline].
Khalsa JH, Genser S, Francis H, Martin B. Clinical consequences of marijuana. J Clin Pharmacol. Nov 2002;42(11 Suppl):7S-10S. [Medline].
Kilpatrick DG, Acierno R, Saunders B, Resnick HS, Best CL, Schnurr PP. Risk factors for adolescent substance abuse and dependence: data from a national sample. J Consult Clin Psychol. Feb 2000;68(1):19-30. [Medline].
Lynskey MT, Heath AC, Bucholz KK, Slutske WS, Madden PA, Nelson EC, et al. Escalation of drug use in early-onset cannabis users vs co-twin controls. JAMA. Jan 22-29 2003;289(4):427-33. [Medline].
McGee R, Williams S, Poulton R, Moffitt T. A longitudinal study of cannabis use and mental health from adolescence to early adulthood. Addiction. Apr 2000;95(4):491-503. [Medline].
McGuigan M. Cannabinoids. In: Goldfrank's Toxicological Emergencies. 8th ed. New York: McGraw-Hill Professional; 2006.
Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry. Oct 2001;58(10):909-15. [Medline].
Robson P. Cannabis. Arch Dis Child. Aug 1997;77(2):164-6. [Medline].
Smith NT. A review of the published literature into cannabis withdrawal symptoms in human users. Addiction. Jun 2002;97(6):621-32. [Medline].
Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA. Mar 6 2002;287(9):1123-31. [Medline].
Strang J, Witton J, Hall W. Improving the quality of the cannabis debate: defining the different domains. BMJ. Jan 8 2000;320(7227):108-10. [Medline].
Vitale S, van de Mheen D. Illicit drug use and injuries: A review of emergency room studies. Drug Alcohol Depend. Mar 15 2006;82(1):1-9. [Medline].
Wallace KL, Kunkel DB. Legal hemp products and urine cannabinoid testing. J Toxicol Clin Toxicol. 1999;37(7):897-8. [Medline].
Watson SJ, Benson JA Jr, Joy JE. Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report. Arch Gen Psychiatry. Jun 2000;57(6):547-52. [Medline].

